1 April 2015: promotion of Venlalic XL to the public
Published 9 June 2015
© Crown copyright 2015
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-april-2015/1-april-2015-promotion-of-venlalic-xl-to-the-public
A member of the public complained that D B Ashbourne Ltd’s website was advertising prescription-only medicines (POMs) to the public.
MHRA did not uphold the complaint.
MHRA noted that the website is accessible to everyone but that it has separate sections for healthcare professionals and the general public. The web page that was mentioned by the complainant included information about costs, bioequivalence and wholesale availability of Venlalic XL Tablets (venlafaxine) that was aimed at healthcare professionals.
D B Ashbourne promptly amended their website so that the pages aimed at healthcare professionals are marked for them.